Here is Why Beam Therapeutics (BEAM) Appears so Attractive

Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside. On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80. This results in a highly attractive upside potential of more than 197%. Looker_Studio/Shutterstock.com Trucchio’s rating is based on several factors linked with the company’s clinical and regulatory progress. He noted the company’s recent agreement with the U.S. FDA to ...